AstraZeneca Investor Day Presentation Deck

Grade 3/4 adverse events 38 Event, n (%) Any grade 3/4 AE (25%) Anemia Neutrophil count decreased Neutropenia Platelet count decreased Cholangitis Thrombocytopenia White blood cell count decreased Any grade 3/4 TRAE (≥2%) Neutrophil count decreased Neutropenia Anemia Platelet count decreased White blood cell count decreased Thrombocytopenia Fatigue Leukopenia Asthenia Durvalumab + GemCis (n=338) 80 (23.7) 71 (21.0) 68 (20.1) 33 (9.8) 22 (6.5) 16 (4.7) 15 (4.4) 70 (20.7) 65 (19.2) 64 (18.9) 27 (8.0) 14 (4.1) 12 (3.6) 9 (2.7) 7 (2.1) 4 (1.2) Placebo + GemCis (n=342) 77 (22.5) 88 (25.7) 72 (21.1) 29 (8.5) 11 (3.2) 18 (5.3) 20 (5.8) 87 (25.4) 69 (20.2) 64 (18.7) 26 (7.6) 20 (5.8) 18 (5.3) 8 (2.3) 2 (0.6) 7 (2.0)

View entire presentation